Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
This study has been completed.
Study NCT00026169 Information provided by National Cancer Institute (NCI)
First Received: November 9, 2001 Last Updated: January 21, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastrointestinal Stromal Tumor
Leukemia
Lymphoma
Myelodysplastic Syndromes
Precancerous/Nonmalignant Condition
Small Intestine Cancer
Additional conditions recognized in this trial
Central Nervous System Neoplasms
Duodenal Neoplasms
Gastrointestinal Stromal Tumors
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Multiple Myeloma
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms, Plasma Cell
Nervous System Neoplasms
Precancerous Conditions
Preleukemia
Syndrome
More general conditions related to this trial
Blood Protein Disorders
Bone Marrow Diseases
Cardiovascular Diseases
Digestive System Diseases
Digestive System Neoplasms
Disease
Duodenal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Ileal Diseases
Immune System Diseases
Immunoproliferative Disorders
Intestinal Diseases
Jejunal Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Nervous System Diseases
Paraproteinemias
Pathologic Processes
Vascular Diseases
Interventions listed in this trial
imatinib mesylate
Additional drug interventions recognized in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Ireland Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
